Case Detail

Case Summary

Reintroduce Thalidomide? (B)

Case Number: 5-104-003(B), Year Published: 2006

HBS Number: KEL059

Request PreviewBuy

Authors: Daniel Diermeier; Jason Hermitage; Shail Thaker; Justin Heinze

Key Concepts

Thalidomide, Healthcare, Pharmaceuticals, Patient Advocacy, Non-Government Organizations, Global


In the 1960s, Thalidomide, a popular new drug considered to be safe and effective, was revealed to cause severe nerve damage and birth defects in new-born infants, prompting health officials to ban the use of the drug and tighten overall restrictions on new drugs and drug use. Twenty years later, after recognizing the positive effects of Thalidomide when treating patients with leprosy and its potential role in treatment of certain types of cancer and cases of HIV/AIDS, the Celgene Corporation would be forced to contend with stringent FDA regulations, liability concerns, public skepticism, and poor mass media portrayal in order to secure the drug’s approval.

Learning Objectives

After students have analyzed the (B) case they should be able to:

  • Refine their ability to analyze a regulation-focused integrated strategy with regard to company objectives, resources, and institutional environment
  • Appreciate the many mutually reinforcing elements that are part of a successful integrated strategy
  • Develop larger-scale integrated strategies to exploit a competitive advantage and/or anticipate and react to market and nonmarket competition from established rivals
  • Number of Pages: 7

    Extended Case Information

    Teaching Areas: Biotechnology, Management, Manufacturing, Strategy

    Teaching Note Available: Yes

    Geographic: United States

    Industry: Pharmaceuticals

    Organization Name: Celgene

    Organization Department: Management

    Organization Size: Large

    Year of Case: 1995